Cytotoxic immune cell-based immunotherapy for hepatocellular carcinoma

Abstract

Hepatocellular carcinoma (HCC) is one of the most common solid tumors with poor clinical prognosis. Novel therapeutic regimens are urgently required for patients with advanced HCC. Both pre-clinical and clinical studies suggest immunotherapy as an attractive alternative for advanced HCC treatment. Natural killer (NK) cells and CD8⁺ T cells are the most important cytotoxic immune cells involved in cancer treatment and elimination. Reinvigorating the anticancer activity of NK and CD8⁺ T cells is the fundamental guarantee for the success of immunotherapy in advanced HCC treatment. Therefore, in this review, we aim to summarize the characteristics and roles of NK and CD8⁺ T cells in HCC development, describe the frontiers of immunotherapy for advanced HCC based on immune checkpoint inhibitors and adoptive cell transfer, and discuss their limitations and scope for future improvement.

Keywords

Hepatocellular carcinoma / immunotherapy / natural killer cells / CD8⁺ T cells

References

[1] Ferlay J,Dikshit R,Mathers C.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012..Int J Cancer2015;136:E359-86

[2] Gosalia AJ,Jones PD.Advances and future directions in the treatment of hepatocellular carcinoma..Gastroenterol Hepatol (N Y)2017;13:398-410 PMCID:PMC5572970

[3] Raoul JL,Finn RS,Reig M.Systemic therapy for intermediate and advanced hepatocellular carcinoma: sorafenib and beyond..Cancer Treat Rev2018;68:16-24

[4] Kudo M,Qin S,Ikeda K.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial..Lancet2018;391:1163-73

[5] Bruix J,Merle P,Huang YH.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial..Lancet2017;389:56-66

[6] Finn RS,Granito A,Bodoky G.Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial..J Hepatol2018;69:353-8

[7] Abou-Alfa GK,Cheng AL,Rimassa L.Cabozantinib in patients with advanced and progressing hepatocellular carcinoma..N Engl J Med2018;379:54-63

[8] Racanelli V.The liver as an immunological organ..Hepatology2006;43:S54-62

[9] Crispe IN.The liver as a lymphoid organ..Ann Rev Immunol2009;27:147-63

[10] Heymann F.Immunology in the liver--from homeostasis to disease..Nat Rev Gastroenterol Hepatol2016;13:88-110

[11] Kubes P.Immune Responses in the Liver..Ann Rev Immunol2018;36:247-77

[12] Makarova-Rusher OV,Duffy AG.The yin and yang of evasion and immune activation in HCC..J Hepatol2015;62:1420-9

[13] Lu C,Zhang B,Wang X.Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities..Mol Cancer2019;18:130 PMCID:PMC6714090

[14] Cherrier DE,Di Santo JP.Innate lymphoid cell development: a T cell perspective..Immunity2018;48:1091-103

[15] Peng H.Re-examining the origin and function of liver-resident NK cells..Trends Immunol2015;36:293-9

[16] Chiossone L,Vienne M.Natural killer cells and other innate lymphoid cells in cancer..Nat Rev Immunol2018;18:671-88

[17] Martinet L.Balancing natural killer cell activation through paired receptors..Nat Rev Immunol2015;15:243-54

[18] Pegram HJ,Smyth MJ,Kershaw MH.Activating and inhibitory receptors of natural killer cells..Immunol Cell Biol2011;89:216-24

[19] Long EO,Liu D,Rajagopalan S.Controlling natural killer cell responses: integration of signals for activation and inhibition..Ann Rev Immunol2013;31:227-58 PMCID:PMC3868343

[20] Cai L,Zhou L,Fu J.Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients..Clin Immunol2008;129:428-37

[21] Sun C,Zhang C.NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma..Cell Mol Immunol2015;12:292-302 PMCID:PMC4654321

[22] Sun C,Huang Q,Wen H.High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer..Oncoimmunology2017;6:e1264562 PMCID:PMC5283631

[23] Sun H,Huang M,Lin R.Human CD96 correlates to natural killer cell exhaustion and predicts the prognosis of human hepatocellular carcinoma..Hepatology2019;70:168-83

[24] Zheng X,Fu B,Jiang Y.Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance..Nat Immunol2019;20:1656-67

[25] Hoechst B,Ormandy L,Zhao F.Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor..Hepatology2009;50:799-807 PMCID:PMC6357774

[26] Wu Y,Pan WD,Lao XM.Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions..Hepatology2013;57:1107-16

[27] Li T,Hua X,Liu W.Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO..Cancer Lett2012;318:154-61

[28] Tian Z,Gao B.Natural killer cells in liver disease..Hepatology2013;57:1654-62 PMCID:PMC3573257

[29] Peng H,Chen Y,Wei H.Liver-resident NK cells confer adaptive immunity in skin-contact inflammation..J Clin Invest2013;123:1444-56 PMCID:PMC3613925

[30] Nakano R,Yano T,Tanaka Y.Hepatic irradiation persistently eliminates liver resident NK cells..PloS One2018;13:e0198904 PMCID:PMC5999234

[31] Stegmann KA,Hansi N,Pallant C.CXCR6 marks a novel subset of T-bet(lo)Eomes(hi) natural killer cells residing in human liver..Sci Rep2016;6:26157 PMCID:PMC4876507

[32] Bai L,Hao X,Sun C.CD8⁺ T cells promote maturation of liver-resident NK cells through the CD70-CD27 axis..Hepatology2019;70:1804-15

[33] Harmon C,Almuaili D,Hoti E.Liver-derived TGF-beta maintains the Eomes(hi)Tbet(lo) phenotype of liver resident natural killer cells..Front Immunol2019;10:1502 PMCID:PMC6616151

[34] Zhou J,Li K,Wang B.Liver-resident NK cells control antiviral activity of hepatic T cells via the PD-1-PD-L1 axis..Immunity2019;50:403-17.e4

[35] Zhao ZB,Ma HD,Yang W.Liver-resident NK cells suppress autoimmune cholangitis and limit the proliferation of CD4⁺ T cells..Cell Mol Immunol2019;17:178-89 PMCID:PMC7000693

[36] Hwang S,Baek JS,Song GW.Cytotoxicity of human hepatic intrasinusoidal CD56^bright natural killer cells against hepatocellular carcinoma cells..Int J Mol Sci2019;20:1564 PMCID:PMC6480584

[37] Easom NJW,Swadling L,Burton AR.IL-15 overcomes hepatocellular carcinoma-induced NK cell dysfunction..Front Immunol2018;9:1009 PMCID:PMC5954038

[38] Sun H,Huang Q,Huang M.Accumulation of tumor-infiltrating CD49a⁺ NK cells correlates with poor prognosis for human hepatocellular carcinoma..Cancer Immunol Res2019;7:1535-46

[39] Saparbay J,Tanimine N,Ohdan H.Everolimus enhances TRAIL-mediated anti-tumor activity of liver resident natural killer cells in mice..Transpl Int2020;33:229-43

[40] Gabrielson A,Wang H,Kallakury B.Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC..Cancer Immunol Res2016;4:419-30 PMCID:PMC5303359

[41] Kalathil SG,Barbi J,Thanavala Y.Augmentation of IFN-gamma+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy..JCI Insight2019;4: PMCID:PMC6693832

[42] Zhou G,Boor PPC,Schutz H.Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas..Gastroenterology2017;153:1107-19.e10

[43] Wang X,Shen H,Sun B.Genetic and phenotypic difference in CD8⁺ T cell exhaustion between chronic hepatitis B infection and hepatocellular carcinoma..J Med Genet2019;56:18-21 PMCID:PMC6327916

[44] Kim HD,Jeong S,Lee H.4-1BB delineates distinct activation status of exhausted tumor-infiltrating CD8⁺ T cells in hepatocellular carcinoma..Hepatology2020;71:955-71

[45] Miller BC,Al Abosy R,Virkud YV.Subsets of exhausted CD8⁺ T cells differentially mediate tumor control and respond to checkpoint blockade..Nat Immunol2019;20:326-36 PMCID:PMC6673650

[46] Siddiqui I,Chennupati V,Calderon-Copete S.Intratumoral Tcf1⁺ PD-1⁺ CD8⁺ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy..Immunity2019;50:195-211.e10

[47] Yang YM,Seki E.Inflammation and liver cancer: molecular mechanisms and therapeutic targets..Semin Liver Dis2019;39:26-42 PMCID:PMC6616367

[48] Lim CJ,Pan L,Chua C.Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma..Gut2019;68:916-27

[49] Yarchoan M,Luan L,Sharma RB.Characterization of the immune microenvironment in hepatocellular carcinoma..Clin Cancer Res2017;23:7333-9 PMCID:PMC5881396

[50] Kalathil S,Miller A,Thanavala Y.Higher frequencies of GARP⁺ CTLA-4⁺ Foxp3⁺ T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality..Cancer Res2013;73:2435-44 PMCID:PMC3645275

[51] Yang L,Jia S,Jin Z.Interleukin-35 dampens CD8⁺ T cells activity in patients with non-viral hepatitis-related hepatocellular carcinoma..Front Immunol2019;10:1032 PMCID:PMC6514160

[52] Huang XY,Shi GM,Zhang C.alphaB-crystallin complexes with 14-3-3zeta to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma..Hepatology2013;57:2235-47

[53] Wang X,Zhangyuan G,Zhang W.14-3-3zeta delivered by hepatocellular carcinoma-derived exosomes impaired anti-tumor function of tumor-infiltrating T lymphocytes..Cell Death Dis2018;9:159 PMCID:PMC5833352

[54] Aliahmad P,Kaye J.The many roles of TOX in the immune system..Curr Opin Immunol2012;24:173-7 PMCID:PMC3319641

[55] Seo H,González-Avalos E,Das A.TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8⁺ T cell exhaustion..Proc Natl Acad Sci U S A2019;116:12410-5 PMCID:PMC6589758

[56] Scott AC,Zumbo P,Klebanoff CA.TOX is a critical regulator of tumour-specific T cell differentiation..Nature2019;571:270-4

[57] Wang X,Shen H,Tian W.TOX promotes the exhaustion of antitumor CD8⁺ T cells by preventing PD1 degradation in hepatocellular carcinoma..J Hepatol2019;71:731-41

[58] Im SJ,Gerner MY,Kissick HT.Defining CD8⁺ T cells that provide the proliferative burst after PD-1 therapy..Nature2016;537:417-21 PMCID:PMC5297183

[59] Gehring AJ,Tan AT,Lee KH.Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma..Gastroenterology2009;137:682-90

[60] Hsu PN,Kao JT,Lee YJ.Increased PD-1 and decreased CD28 expression in chronic hepatitis B patients with advanced hepatocellular carcinoma..Liver Int2010;30:1379-86

[61] Xiao X,Chen MM,Wei Y.PD-1hi Identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression..Cancer Discov2016;6:546-59

[62] Lim TS,Sieow JL,Yeong JP.PD-1 expression on dendritic cells suppresses CD8⁺ T cell function and antitumor immunity..Oncoimmunology2016;5:e1085146 PMCID:PMC4839350

[63] Gao Q,Qiu SJ,Sho M.Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma..Clin Cancer Res2009;15:971-9

[64] Jung HI,Ji S,Bae SH.Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma..Cancer Res Treat2017;49:246-54 PMCID:PMC5266389

[65] Wu K,Chen L,Welling TH.Kupffer cell suppression of CD8⁺ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions..Cancer Res2009;69:8067-75 PMCID:PMC4397483

[66] Shi F,Zeng Z,Liu ZW.PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients..Int J Cancer2011;128:887-96

[67] Kuang DM,Zhao Q,Li XF.B7-H1-expressing antigen-presenting cells mediate polarization of protumorigenic Th22 subsets..J Clin Invest2014;124:4657-67 PMCID:PMC4191045

[68] Xia Y,Ye SL,Chen J.Inhibition of T-cell responses by intratumoral hepatic stellate cells contribute to migration and invasion of hepatocellular carcinoma..Clin Exp Metastasis2011;28:661-74

[69] He G,Zhou J,Chen Y.Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma..J Exp Clin Cancer Res2015;34:141 PMCID:PMC4652417

[70] El-Khoueiry AB,Yau T,Kudo M.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial..Lancet2017;389:2492-502

[71] Zhu AX,Edeline J,Ogasawara S.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial..Lancet Oncol2018;19:940-52

[72] Finn RS,Merle P,Bouattour M.Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, Phase III trial..J Clin Oncol2020;38:193-202

[73] Cheng AL,Chan SL,Kudo M.Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma..J Hepatol2020;72:307-19

[74] Floudas CS,Greten TF.Immunotherapy: current status and future perspectives..Dig Dis Sci2019;64:1030-40

[75] Reck M,Nishio M,Cappuzzo F.Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial..Lancet Respir Med2019;7:387-401

[76] Chau I,Borg C,Seitz JF.Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: patient-focused outcome results from the randomised phase III REACH study..Eur J Cancer2017;81:17-25

[77] Krummel MF.CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation..J Exp Med1995;182:459-65 PMCID:PMC2192127

[78] Liu Z,Sun J,Li C.Association between CTLA-4 rs231775 polymorphism and hepatocellular carcinoma susceptibility..Int J Clin Exp Pathol2015;8:15118-22 PMCID:PMC4713639

[79] Chen X,Hu Q.Tumor-derived CD4⁺CD25⁺regulatory T cells inhibit dendritic cells function by CTLA-4..Pathol Res Pract2017;213:245-9

[80] Han Y,Yang Y,Gu Y.Human CD14⁺ CTLA-4⁺ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma..Hepatology2014;59:567-79

[81] Pedroza-Gonzalez A,Singh SP,Pan Q.GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo..Oncoimmunology2015;4:e1051297 PMCID:PMC4635937

[82] Sangro B,de la Mata M,Garralda E.A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C..J Hepatol2013;59:81-8

[83] Duffy AG,Makorova-Rusher O,Wedemeyer H.Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma..J Hepatol2017;66:545-51 PMCID:PMC5316490

[84] Yau T,Kim TY,Santoro A.Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040..J Clin Oncol2019;37:4012

[85] Kaseb A,Blando J,Ikoma N.Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC..Ann Oncol2019;30:iv112

[86] Hellmann MD,Bernabe Caro R,Kim SW.Nivolumab plus ipilimumab in advanced non-small-cell lung cancer..N Engl J Med2019;381:2020-31

[87] Purdy AK.Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR)..Cancer Biol Ther2009;8:2211-20 PMCID:PMC2825280

[88] Cariani E.KIR/HLA immunogenetic background influences the evolution of hepatocellular carcinoma..Oncoimmunology2013;2:e26622 PMCID:PMC3913692

[89] Pan N,Sun H,Shi Q.Combination of human leukocyte antigen and killer cell immunoglobulin-like receptor genetic background influences the onset age of hepatocellular carcinoma in male patients with hepatitis B virus infection..Clin Dev Immunol2013;2013:874514 PMCID:PMC3842051

[90] Vey N,Sadot-Lebouvier S,Berton-Rigaud D.A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies..Oncotarget2018;9:17675-88 PMCID:PMC5915148

[91] Benson DM Jr,Padmanabhan S,Jagannath S.A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma..Blood2012;120:4324-33 PMCID:PMC3507143

[92] van Montfoort N,Korrer MJ,Marijt KA.NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines..Cell2018;175:1744-55.e15 PMCID:PMC6354585

[93] Xu HC,Pandyra AA,Zhuang Y.Lymphocytes negatively regulate NK cell activity via Qa-1b following viral infection..Cell Rep2017;21:2528-40

[94] André P,Soulas C,Lopez J.Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells..Cell2018;175:1731-43.e13 PMCID:PMC6292840

[95] Kamiya T,Wong D,Campana D.Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells..J Clin Invest2019;129:2094-106 PMCID:PMC6486333

[96] Zhang Q,Zheng X,Wang H.Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity..Nat Immunol2018;19:723-32

[97] Stanietsky N,Arapovic J,Levy O.The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity..Proc Natl Acad Sci U S A2009;106:17858-63 PMCID:PMC2764881

[98] Molgora M,Ponzetta A,Barbagallo M.IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity..Nature2017;551:110-4 PMCID:PMC5768243

[99] Ndhlovu LC,Barbour JD,Jha AR.Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity..Blood2012;119:3734-43 PMCID:PMC3335380

[100] Chan CJ,Gilfillan S,Chow MT.The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions..Nat Immunol2014;15:431-8

[101] Zhao Q,He M,Kuang DM.BTLA identifies dysfunctional PD-1-expressing CD4⁺ T cells in human hepatocellular carcinoma..Oncoimmunology2016;5:e1254855 PMCID:PMC5214739

[102] Wang J,Liu LN,Nie X.Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy..Nat Med2019;25:656-66

[103] Wehrenberg-Klee E,Dugan M,Ganguli S.Y-90 radioembolization combined with a PD-1 inhibitor for advanced hepatocellular carcinoma..Cardiovasc Intervent Radiol2018;41:1799-802

[104] Shigeta K,Hato T,Chen IX.Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma..Hepatology2019; PMCID:PMC7000304

[105] Sawada Y,Shimomura M,Endo I.Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes..Int J Oncol2015;46:28-36 PMCID:PMC4238729

[106] Ljunggren HG.In search of the ‘missing self’: MHC molecules and NK cell recognition..Immunol Today1990;11:237-44

[107] Shifrin N,Ardolino M.NK cell self tolerance, responsiveness and missing self recognition..Semin Immunol2014;26:138-44 PMCID:PMC3984600

[108] Rosenberg SA,Muul LM,Chang AE.Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer..N Engl J Med1985;313:1485-92

[109] Miller JS,Panoskaltsis-Mortari A,Yun GH.Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer..Blood2005;105:3051-7

[110] Romee R,Berrien-Elliott MM,Jewell BA.Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia..Sci Transl Med2016;8:357ra123 PMCID:PMC5436500

[111] Lin M,Wang X,Zhang M.Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer..Oncotarget2017;8:81967-77 PMCID:PMC5669863

[112] Tonn T,Klingemann HG,Esser R.Treatment of patients with advanced cancer with the natural killer cell line NK-92..Cytotherapy2013;15:1563-70

[113] Romanski A,Bug G,Klingemann H.CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies..J Cell Mol Med2016;20:1287-94 PMCID:PMC4929308

[114] Yu M,Fan M,Shi B.Development of GPC3-specific chimeric antigen receptor-engineered natural killer cells for the treatment of hepatocellular carcinoma..Mol Ther2018;26:366-78 PMCID:PMC5835122

[115] Xiao Z,Feng JH,Wang YZ.Effectiveness and safety of chemotherapy with cytokine-induced killer cells in non-small cell lung cancer: a systematic review and meta-analysis of 32 randomized controlled trials..Cytotherapy2019;21:125-47

[116] Jia CC,Cai XR,Zheng XF.Efficacy of cytokine-induced killer cell-based immunotherapy for hepatocellular carcinoma..Am J Cancer Res2019;9:1254-65 PMCID:PMC6610062

[117] Lee JH,Lim YS,Song TJ.Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma..Gastroenterology2015;148:1383-91.e6

[118] Lee JH,Lim YS,Song TJ.Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up..Cancer Immunol Immunother2019;68:23-32 PMCID:PMC6326973

[119] Chang B,Wang K,Huang T.High number of PD-1 positive intratumoural lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients..Liver Int2018;38:1449-58 PMCID:PMC6099434

[120] Pan QZ,Zhou YQ,Wang QJ.CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma..Cancer Immunol Immunother2020;Epub ahead of print. doi:10.1007/s00262-020-02486-y

[121] Wang XP,Gao HF,Xu KC.Intraperitoneal perfusion of cytokine-induced killer cells with local hyperthermia for advanced hepatocellular carcinoma..World J Gastroenterol2013;19:2956-62 PMCID:PMC3660821

[122] Liu Y,Han W.Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia..Drugs Today (Barc)2017;53:597-608

[123] Zhu ZW,Wang L,Zimmermann A.Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders..Gut2001;48:558-64 PMCID:PMC1728256

[124] Filmus J.Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma..FEBS J2013;280:2471-6

[125] Abou-Alfa GK,Daniele B,Merle P.Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma..J Hepatol2016;65:289-95

[126] Ishiguro T,Komatsu SI,Kaneko A.An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors..Sci Transl Med2017;9:eaal4291

[127] Gao H,Tu H,Jiang H.Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma..Clin Cancer Res2014;20:6418-28

[128] Guo X,Shi B,Zhang H.Disruption of PD-1 enhanced the anti-tumor activity of chimeric antigen receptor T cells against hepatocellular carcinoma..Front Pharmacol2018;9:1118 PMCID:PMC6174208

[129] Pan Z,Shi B,Shi Z.Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein..Cancer Immunol Immunother2018;67:1621-34

[130] Hu W,Huang X,Hao L.Chimeric antigen receptor modified T cell (CAR-T) co-expressed with ICOSL-41BB promote CAR-T proliferation and tumor rejection..Biomed Pharmacother2019;118:109333

[131] Chen Y,Gong ZW,Wang ZX.Chimeric antigen receptor-engineered T-cell therapy for liver cancer..Hepatobiliary Pancreat Dis Int2018;17:301-9

[132] Sun B,Dai H,Jia R.Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells..Cancer Immunol Res2019;7:1813-23

[133] Zhang RY,Liu ZK,Wei W.Doxycycline inducible chimeric antigen receptor T cells targeting CD147 for hepatocellular carcinoma therapy..Front Cell Dev Biol2019;7:233 PMCID:PMC6798074

[134] Qasim W,Gehring AJ,Schurich A.Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient..J Hepatol2015;62:486-91

[135] Spear TT,Roszkowski JJ,Simms PE.TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors..Cancer Immunol Immunother2016;65:293-304 PMCID:PMC4887146

[136] Zhu W,Wang L,Jiang X.Identification of alpha-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy..Hepatology2018;68:574-89

[137] Spear TT,Baker BM.Understanding TCR affinity, antigen specificity, and cross-reactivity to improve TCR gene-modified T cells for cancer immunotherapy..Cancer Immunol Immunother2019;68:1881-9

[138] Tendeiro Rego R,Lowdell MW.T-cell receptor gene-modified cells: past promises, present methodologies and future challenges..Cytotherapy2019;21:341-57

[139] Palmer DH,Mirza N,Ahmed F.A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma..Hepatology2009;49:124-32

[140] Butterfield LH,Dissette VB,Yang JQ.A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides..Clin Cancer Res2006;12:2817-25

[141] Tada F,Hirooka M,Hiasa Y.Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma..Int J Oncol2012;41:1601-9 PMCID:PMC3583872

[142] Lee JH,Lee M,Song JS.A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma..Br J Cancer2015;113:1666-76 PMCID:PMC4702003

[143] Lee JH,Lee Y,Song JS.Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study..Oncoimmunology2017;6:e1328335 PMCID:PMC5543846

[144] Lu Z,Jing R,Rao Q.Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models..J Hepatol2017;67:739-48

[145] Pang YB,Cui BY,Li XL.A potential antitumor effect of dendritic cells fused with cancer stem cells in hepatocellular carcinoma..Stem Cells Int2019;2019:5680327 PMCID:PMC6466848

[146] Kodumudi KN,Weber AM,Sarnaik AA.Immune checkpoint blockade to improve tumor infiltrating lymphocytes for adoptive cell therapy..PloS One2016;11:e0153053 PMCID:PMC4822778

[147] John LB,Duong CP,Beavis PA.Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells..Clin Cancer Res2013;19:5636-46

[148] Mahvi DA,Tatar AJ,Suresh M.Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice..J Immunother2015;38:54-61 PMCID:PMC4321765

[149] Jung IY.Unleashing the therapeutic potential of CAR-T cell therapy using gene-editing technologies..Mol Cells2018;41:717-23 PMCID:PMC6125425

[150] Zhang R,Liu Z,Wu X.Adoptive cell transfer therapy for hepatocellular carcinoma..Front Med2019;13:3-11